by The Small Scale Bioreactors Market is estimated to be valued at US$ 1508.86 Mn in 2023 and is expected to exhibit a CAGR of 10.% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Small scale bioreactors are benchtop bioreactors used for cultivating microbial, mammalian, plant, and insect cells on a small scale for research studies. They are used for development, optimization and production runs for applications such as monoclonal antibodies, viral vectors, vaccines, and cell therapy products. These bioreactors allow for controlled conditions like temperature, pH, oxygen level, and stirring for optimal cell growth.
Market Dynamics:
Increasing R&D investment in cell-based research: Government organizations and private companies are increasingly investing in cell-based research for developing new therapies for diseases like cancer. Growing demand for cost-effective production: Small scale bioreactors provide cost-effective production of cells, viruses and gene therapy vectors in small quantities for research applications compared to large scale bioreactors. They reduce overall project cost and time by enabling parallel experimentation. Adoption of single-use technologies: Single-use bioreactors are increasingly preferred over stainless steel bioreactors due to advantages like reduced cleaning & sterilization efforts. As SSBRs require media replacement for every process, single-use bioreactors are a more economical option for small scale production.
Segment Analysis
The small scale bioreactors market is segmented into benchtop and laboratory scale bioreactors based on type. The laboratory scale bioreactors segment dominated the market in 2023 owing to increasing research activities in biopharmaceutical companies for new drug development. Laboratory scale bioreactors provide flexibility and are cost-effective solutions for R&D and initial process development.
PEST Analysis
Political: Regulations regarding quality standards and safety of biologics production and testing impact the market. Favorable regulatory environment for biologics manufacturing boosts adoption.
Economic: Rising healthcare expenditure globally on chronic disease management fuels market growth. However, high costs associated may hinder the smaller players.
Social: Increasing incidence of diseases such as cancer, diabetes boosts demand for biologics and cell therapies driving the need for bioreactors in production.
Technological: Advancements in control systems, monitoring and data acquisition have made bioreactors more efficient and scalable. Online monitoring enables better process understanding.
Key Takeaways
The global Small Scale Bioreactors Market Growth is expected to witness high growth, exhibiting CAGR of 10% over the forecast period, due to increasing prevalence of chronic diseases. The market size for 2023 is US$ 1508.86 Mn.
Regional analysis: North America dominated the market in 2023 due to presence of major biotech companies and huge demand for biologics. Asia Pacific exhibits highest CAGR during the forecast period with increasing government support for drug development in countries like China and India.
Key players: Key players operating in the small scale bioreactors market are Merck KGaA ,Danaher Corporation, Getinge AB, Sartorius AG ,Thermo Fisher Scientific Inc. , Lonza Group , Eppendorf AG , Miltenyi Biotec ,Solaris Biotechnology Srl, Infors AG, Biosan, MicroDigital Co. Ltd., 2mag AG, MDX Biotechnik International GmbH, Esco Lifesciences Group, HiTec Zang GmbH, Hanil Scientific Inc., Adolf KÃ1⁄4hner AG, Ori Biotech , Aglaris and AdvaBio. Major players focus on new product launches and geographical expansion to gain more revenue share.
